The tyrosine kinase inhibitor Imatinib selectively targets the ATP binding site of Bcr Abl. Based on numerous clinical studies, Imatinib has moved towards first-line therapy for traditional treatment of CML. But, the emergence of resistance selective c-Met inhibitor to IM remains a major problem in the course of treatment of CML and does occur often in blast crisis and accelerated phase causing remissions frequently lasting for only 6-12 months. Different components of IM opposition have now been identified, including BCR ABL gene amplification which leads to overexpression of the Bcr Abl protein, point mutations within the Bcr Abl kinase domain which restrict IM binding, and point mutations not in the kinase domain which allosterically inhibit IM binding to Bcr Abl. Second-generation Bcr Abl inhibitors such as dasatinib, nilotinib, and bosutinib are competent to overcome many these resistances. Nevertheless, none of those second generation Bcr Abl inhibitors considerably inhibits the growth of leukemia cells harbouring the mutation. As this is one of the most typical variations present in patients undergoing IM treatment Infectious causes of cancer and responsible for approximately 20% of the technically noticed resistances the develop-ment of alternative therapeutic methods becomes an important goal. Aurora kinases are key regulators of mitosis. However, dysregulated expression of the enzymes results in aneuploidy and carcinogenesis. Recently, the Aurora kinase inhibitors VX 680/MK 0457 and PHA 739358 have been demonstrated to be active ex vivo against cells from patients bearing the ABL T315I mutation. In-addition, the anti proliferative results of VX 680/MK 0457 were confirmed clinically in-patients harbouring T315I mutated BCR ABL. Here, we report on a novel natural product libraries kinase inhibitor PHA 680626 exhibiting strong inhibitory activity on both Bcr Abl and Aurora kinases. In order to evaluate the mechanism of action of the novel therapeutic agent and to look for the relative share of the inhibition of Bcr Abl instead of Aurora kinase on its therapeutic effectivity, we analyzed the antiproliferative and pro apoptotic consequences along with its impact on Bcr Abl and Aurora kinase signaling in IM sensitive and resistant leukemic cell lines. Moreover, effectiveness of PHA680626 was tried in principal CD34 cells derived from patients initially analysis of CML or in blast crisis along with from someone harbouring the IM immune T315I mutation. Imatinib, a derivative of 2 phenylaminopyrimidine,was obtained from Dr. E. Buchdunger,Novartis, Basel, Switzerland. For mix studies, IM was bought from Toronto Re-search Chemicals, Inc, Ontario, Canada. PHA 680626 was kindly provided by Nerviano Medical Sciences, Milan, Italy. PHA 680626 stock solution and im stock solution were stored at 20 C.